Oncology

Since 2004, the FDA has approved different treatments for advanced prostate cancer, adding almost 2-3 indications per year for the past 15 years.

A study suggests that even brief art-making interventions can be beneficial for stressed caregivers of patients with cancer.

According to the study authors, such “anti-austerity agents” represent a promising approach to cancer chemotherapy.

By entering clinical and disease characteristics into a learning algorithm, researchers were able to create an efficacy prediction for CDK inhibitors.

Abemaciclib is a potent oral cyclin-dependent kinase 4/6 inhibitor that has previously demonstrated statistically significant improvement in PFS and ORR in combination with endocrine therapy.

Rita Nanda, MD, explains how researchers are aiming to make immunologically silent tumors more inflamed. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.

Banu Arun, MD, explains the potential risks of passive genetic counseling via videos or at-home tests. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.

Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and Merck) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Researchers may have found a way to stop the driving force at a molecular level behind acute lymphoblastic leukemia.

According to results from the CORALLEEN trial presented at the San Antonio Breast Cancer Symposium, neoadjuvant treatment with the cyclin-dependent-kinase (CDK) 4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to multi-agent chemotherapy in patients with high-risk luminal B breast cancer.

Banu Arun, MD, explains the various reasons for the lack of genetic testing in appropriate candidates. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.

Oncolytic Viral Therapy (OVT) is currently not recognized by treatment guidelines for advanced pancreatic cancer; however, safety and efficacy data from previous studies conducted over the previous 10 years have shown that OVT may be a promising, innovative approach for patients with pancreatic cancer.

A study found that the total prescriptions for gabapentinoid medications grew from 1.2 million to 3.5 million between 2005-2015.

Abemacilib is an oral selective inhibitor of cyclin-dependent kinases 4 and 6 approved for hormone receptor, human epidermal growth factor receptor 2 metastatic breast cancer.

Enfortumab vedotin-ejfv is the first FDA-approved treatment in the United States for this patient population.

A study evaluated the real-world benefit of palbociclib plus endocrine therapy as a first-line treatment in HR-positive, HER2-negative metastatic breast cancer to correlate the efficacy of the combination with neutropenia.

Patricia Spears discusses the various approaches to discussing clinical trials, and in which situations to use them. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.

Researchers have confirmed that the addition of the CDK4/6 inhibitor abemaciclib to aromatase inhibitors is associated with durable tumor responses.

Dawn Hershman, MD, MS, discusses various reasons for non-adherence to endocrine therapy in breast cancer patients. This video was filmed December 13 at the 2019 San Antonio Breast Cancer Symposium.

The EGFR/RAS/MEK pathway may serve as a predictive biomarker for palbociclib plus fulvestrant resistance and offer therapeutic targets to overcome resistance in patients with ER-positive/HER2-negative breast cancer.

Researchers used an epidermal growth factor (EGF)-conjugated anthrax toxin that, after targeting EGFR, was internalized and triggered apoptosis in exposed bladder cancer cells.

In order to improve the efficacy of checkpoint blockade treatments in patients with breast cancer, it is necessary to consider treatment through the lens of the cancer immunity cycle.

Banu Arun, MD, explains why genetic testing is important and its intended uses for treatment in patients with breast cancer during the 2019 San Antonio Breast Cancer Symposium.

Transform Oncology Care uses results of broad-panel gene sequencing tests to help oncologists identify appropriate treatment regimens based on their patients clinical and genetic profiles.

The study results were presented at the 2019 San Antonio Breast Cancer Symposium, held December 10 through 14.

Despite the fact that menopausal hormone therapy with estrogen plus progestin is frequently used, its influence on breast cancer incidence and mortality has been debated, with discordant findings from prospective observational studies compared with randomized clinical trials.

Peter Schmid, FRCP, MD, PhD, discusses the 5 most common immune-related side effects seen in breast cancer patients. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.

Although there is no standard of care therapy following second-line treatment for human epidermal growth receptor 2 (HER2)-positive breast cancer, there are a number of options being researched.